PBRM1 and nonpapillary renal cell carcinoma: Additionally, loss-of-function (LOF) PBRM1 mutations in ccRCC patients are associated with increased efficacy of ICB therapy (41, 42), where the WT protein is implicated in reduced response to ICB (41, 43, 44).